Payment overview · 2025
General Payments
$228.62
12 reported records · 7 companies
Healthcare provider profile · identity verified
Randall T Huling, MD
Allopathic & Osteopathic Physicians|Family Medicine · OLIVE BRANCH, MS · NPI 1316936917
Verified facts
What the public records show
CMS Open Payments records show Randall T Huling, MD received $228.62 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.88 | 22.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.65 | 20.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.80 | 16.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.40 | 12.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $29.11 | 12.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.75 | 9.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.03 | 4.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $228.62 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.88 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.03 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 249 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 87 |
| Gabapentin | Gabapentin | 174 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 150 | 50 |
| Losartan Potassium | Losartan Potassium | 147 | 58 |
| Metformin Hcl | Metformin Hcl | 141 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 47 |
| Omeprazole | Omeprazole | 119 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 46 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 98 | 89 |
| Furosemide | Furosemide | 87 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 24 |
| Simvastatin | Simvastatin | 82 | 29 |
| Eliquis | Apixaban | 79 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 17 |
| Meloxicam | Meloxicam | 72 | 30 |
| Lisinopril | Lisinopril | 70 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 24 |
| Carvedilol | Carvedilol | 65 | 26 |
| Tramadol Hcl | Tramadol Hcl | 65 | 21 |
| Potassium Chloride | Potassium Chloride | 60 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 20 |
| Sertraline Hcl | Sertraline Hcl | 58 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 26 |
| Famotidine | Famotidine | 54 | 23 |
| Alprazolam | Alprazolam | 53 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Allopurinol | Allopurinol | 46 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 23 |
| Trulicity | Dulaglutide | 45 | 11 |
| Ezetimibe | Ezetimibe | 44 | 17 |
| Alendronate Sodium | Alendronate Sodium | 42 | 15 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 20 |
| Montelukast Sodium | Montelukast Sodium | 38 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 16 |
| Donepezil Hcl | Donepezil Hcl | 36 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 14 |
| Finasteride | Finasteride | 31 | 12 |
| Jardiance | Empagliflozin | 31 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 16 |
| Glimepiride | Glimepiride | 30 | 11 |
| Memantine Hcl | Memantine Hcl | 30 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Chlorthalidone | Chlorthalidone | 29 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 18 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 12 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Tdvax | Tetanus, Diphtheria Tox,adult | 11 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.62 · 12 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, COMIRNATY, FARXIGA, IBSRELA, Ozempic, PREVNAR 20, VOQUEZNA, VRAYLAR, WATCHMAN FLX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error